Judge denies Amphastar’s motion to stay PI pending appeal; NVS, MNTA agree on split of $100M Court bond; MNTA’s new ‘235 patent may be workaround to Teva’s “Gad” patents; 2012-2013 news flow; musings on Lovenox pricing since launch of SNY’s AG; phase-3 Lemtrada data in second-line RRMS; table of major shareholders; table of insider shareholdings and options; new version of “How will Xarelto/Eliquis/Pradaxa affect US Lovenox sales?”; new version of “What’s New in the Anticoagulant Arena?”
DD, I don't believe the motion to stay the PI pending appeal has been decided yet. The last doc I saw set the briefing schedule and denied Amphastar's request for an "immediate stay" pending decision on the formal motion.
That’s correct. I.e., the Appellate Court could conceivably grant Amphastar’s motion for a stay of the PI pending the appeal of the PI ruling even though the Appellate Court denied Amphastar’s request for a stay of the PI on an “emergency” basis. Not likely, however.
I’ll change the info in the ‘ReadMeFirst’ accordingly.